Biologics and Biosimilars (eBook, PDF)
Drug Discovery and Clinical Applications
Redaktion: Feng, Xiaodong; Yang, Catherine F.; Malhotra, Ashim; Xie, Hong-Guang
48,95 €
48,95 €
inkl. MwSt.
Sofort per Download lieferbar
24 °P sammeln
48,95 €
Als Download kaufen
48,95 €
inkl. MwSt.
Sofort per Download lieferbar
24 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
48,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
24 °P sammeln
Biologics and Biosimilars (eBook, PDF)
Drug Discovery and Clinical Applications
Redaktion: Feng, Xiaodong; Yang, Catherine F.; Malhotra, Ashim; Xie, Hong-Guang
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This is a good book designed mainly to give students and clinicians a quick overview of the science, principles, and applications of biologics and biosimilars. It is a useful tool in the clinic setting.
- Victor Nwoko , BA, PharmD, Lifespring Pharmacy Inc.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 18.54MB
This is a good book designed mainly to give students and clinicians a quick overview of the science, principles, and applications of biologics and biosimilars. It is a useful tool in the clinic setting.
- Victor Nwoko, BA, PharmD, Lifespring Pharmacy Inc.
- Victor Nwoko, BA, PharmD, Lifespring Pharmacy Inc.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 528
- Erscheinungstermin: 13. Juni 2022
- Englisch
- ISBN-13: 9780429939297
- Artikelnr.: 63954973
- Verlag: Taylor & Francis
- Seitenzahl: 528
- Erscheinungstermin: 13. Juni 2022
- Englisch
- ISBN-13: 9780429939297
- Artikelnr.: 63954973
Xiaodong Feng, Hong-Guang Xie, Ashim Malhotra, Catherine F. Yang
Chapter 1: Biologics and Biosimilars 101: Principles and Practice. Chapter
2: Frontiers in Biopharmaceutical Development of Biologics and Biosimilars:
Opportunities and Challenges Chapter 3: Biologics and Biosimilars: Research
and Development. Chapter 4: Vaccines as Biologics in the Era of Pandemic.
Chapter 5: Therapeutic Delivery Systems for Biologics and Biosimilars.
Chapter 6: Legislative and Regulatory Pathways for Biosimilars. Chapter 7:
The Development of Biologics from the Perspective of the Pharmaceutical
Industry. Chapter 8: The Manufacturing and Quality Assurance Process for
Biologics and Biosimilars. Chapter 9: Biopharmaceutics, Pharmacokinetics,
and Pharmacodynamics of Biological Products. Chapter 10: Understanding
Variability, Stability, and Immunogenicity of Biosimilars. Chapter 11:
Expanding the Product Shelf: Taking Biologics and Biosimilars from the
Bench to the Bedside. Chapter 12: Hydrogel-Based Delivery of Biologics in
Cancer and Cardiovascular Diseases: Proof-of-Concept. Chapter 13: Clinical
Use of Biologics and Biosimilars in Oncology Settings. Chapter 14:
Monoclonal Antibodies in Cancer Therapeutics. Chapter 15: Molecule-Targeted
Drugs That Treat Colorectal Cancer. Chapter 16: Rising from the Ashes: The
Curious Case of the Development of Biologics for the Treatment of
Neuroblastoma. Chapter 17: Paradigm Shift in Cancer Therapy: Chimeric
Antigen Receptor T Cell Therapy. Chapter 18: Biologics and Biosimilars Used
for Diabetes. Chapter 19: Clinical Use of Biologics and Biosimilars in
Asthma. Chapter 20: Biologics and Biosimilars: Potential Therapeutics for
Autoimmune Renal Diseases. Chapter 21: Therapeutics of Recombinant Human
Clotting Factor VIII (rhFVIII) for Hemophilia A. Chapter 22: Complement as
New Immunotherapy Target: Past, Present, and Future. Chapter 23: Drug
Discovery Approaches for Inflammatory Bowel Disease: Antibodies and
Biosimilars. Chapter 24: Transformative Stem Cell-Based Therapy in
Neurological Diseases and Beyond. Chapter 25: Biologics and Biosimilars:
Clinical Applications and Biomarker Testing. Chapter 26: Application of
Modeling and Simulation in the Development of Biologics and Biosimilars.
Chapter 27 Machine Learning Applications in Biologics and Biosimilars:
Disruptive Innovation.
2: Frontiers in Biopharmaceutical Development of Biologics and Biosimilars:
Opportunities and Challenges Chapter 3: Biologics and Biosimilars: Research
and Development. Chapter 4: Vaccines as Biologics in the Era of Pandemic.
Chapter 5: Therapeutic Delivery Systems for Biologics and Biosimilars.
Chapter 6: Legislative and Regulatory Pathways for Biosimilars. Chapter 7:
The Development of Biologics from the Perspective of the Pharmaceutical
Industry. Chapter 8: The Manufacturing and Quality Assurance Process for
Biologics and Biosimilars. Chapter 9: Biopharmaceutics, Pharmacokinetics,
and Pharmacodynamics of Biological Products. Chapter 10: Understanding
Variability, Stability, and Immunogenicity of Biosimilars. Chapter 11:
Expanding the Product Shelf: Taking Biologics and Biosimilars from the
Bench to the Bedside. Chapter 12: Hydrogel-Based Delivery of Biologics in
Cancer and Cardiovascular Diseases: Proof-of-Concept. Chapter 13: Clinical
Use of Biologics and Biosimilars in Oncology Settings. Chapter 14:
Monoclonal Antibodies in Cancer Therapeutics. Chapter 15: Molecule-Targeted
Drugs That Treat Colorectal Cancer. Chapter 16: Rising from the Ashes: The
Curious Case of the Development of Biologics for the Treatment of
Neuroblastoma. Chapter 17: Paradigm Shift in Cancer Therapy: Chimeric
Antigen Receptor T Cell Therapy. Chapter 18: Biologics and Biosimilars Used
for Diabetes. Chapter 19: Clinical Use of Biologics and Biosimilars in
Asthma. Chapter 20: Biologics and Biosimilars: Potential Therapeutics for
Autoimmune Renal Diseases. Chapter 21: Therapeutics of Recombinant Human
Clotting Factor VIII (rhFVIII) for Hemophilia A. Chapter 22: Complement as
New Immunotherapy Target: Past, Present, and Future. Chapter 23: Drug
Discovery Approaches for Inflammatory Bowel Disease: Antibodies and
Biosimilars. Chapter 24: Transformative Stem Cell-Based Therapy in
Neurological Diseases and Beyond. Chapter 25: Biologics and Biosimilars:
Clinical Applications and Biomarker Testing. Chapter 26: Application of
Modeling and Simulation in the Development of Biologics and Biosimilars.
Chapter 27 Machine Learning Applications in Biologics and Biosimilars:
Disruptive Innovation.
Chapter 1: Biologics and Biosimilars 101: Principles and Practice. Chapter
2: Frontiers in Biopharmaceutical Development of Biologics and Biosimilars:
Opportunities and Challenges Chapter 3: Biologics and Biosimilars: Research
and Development. Chapter 4: Vaccines as Biologics in the Era of Pandemic.
Chapter 5: Therapeutic Delivery Systems for Biologics and Biosimilars.
Chapter 6: Legislative and Regulatory Pathways for Biosimilars. Chapter 7:
The Development of Biologics from the Perspective of the Pharmaceutical
Industry. Chapter 8: The Manufacturing and Quality Assurance Process for
Biologics and Biosimilars. Chapter 9: Biopharmaceutics, Pharmacokinetics,
and Pharmacodynamics of Biological Products. Chapter 10: Understanding
Variability, Stability, and Immunogenicity of Biosimilars. Chapter 11:
Expanding the Product Shelf: Taking Biologics and Biosimilars from the
Bench to the Bedside. Chapter 12: Hydrogel-Based Delivery of Biologics in
Cancer and Cardiovascular Diseases: Proof-of-Concept. Chapter 13: Clinical
Use of Biologics and Biosimilars in Oncology Settings. Chapter 14:
Monoclonal Antibodies in Cancer Therapeutics. Chapter 15: Molecule-Targeted
Drugs That Treat Colorectal Cancer. Chapter 16: Rising from the Ashes: The
Curious Case of the Development of Biologics for the Treatment of
Neuroblastoma. Chapter 17: Paradigm Shift in Cancer Therapy: Chimeric
Antigen Receptor T Cell Therapy. Chapter 18: Biologics and Biosimilars Used
for Diabetes. Chapter 19: Clinical Use of Biologics and Biosimilars in
Asthma. Chapter 20: Biologics and Biosimilars: Potential Therapeutics for
Autoimmune Renal Diseases. Chapter 21: Therapeutics of Recombinant Human
Clotting Factor VIII (rhFVIII) for Hemophilia A. Chapter 22: Complement as
New Immunotherapy Target: Past, Present, and Future. Chapter 23: Drug
Discovery Approaches for Inflammatory Bowel Disease: Antibodies and
Biosimilars. Chapter 24: Transformative Stem Cell-Based Therapy in
Neurological Diseases and Beyond. Chapter 25: Biologics and Biosimilars:
Clinical Applications and Biomarker Testing. Chapter 26: Application of
Modeling and Simulation in the Development of Biologics and Biosimilars.
Chapter 27 Machine Learning Applications in Biologics and Biosimilars:
Disruptive Innovation.
2: Frontiers in Biopharmaceutical Development of Biologics and Biosimilars:
Opportunities and Challenges Chapter 3: Biologics and Biosimilars: Research
and Development. Chapter 4: Vaccines as Biologics in the Era of Pandemic.
Chapter 5: Therapeutic Delivery Systems for Biologics and Biosimilars.
Chapter 6: Legislative and Regulatory Pathways for Biosimilars. Chapter 7:
The Development of Biologics from the Perspective of the Pharmaceutical
Industry. Chapter 8: The Manufacturing and Quality Assurance Process for
Biologics and Biosimilars. Chapter 9: Biopharmaceutics, Pharmacokinetics,
and Pharmacodynamics of Biological Products. Chapter 10: Understanding
Variability, Stability, and Immunogenicity of Biosimilars. Chapter 11:
Expanding the Product Shelf: Taking Biologics and Biosimilars from the
Bench to the Bedside. Chapter 12: Hydrogel-Based Delivery of Biologics in
Cancer and Cardiovascular Diseases: Proof-of-Concept. Chapter 13: Clinical
Use of Biologics and Biosimilars in Oncology Settings. Chapter 14:
Monoclonal Antibodies in Cancer Therapeutics. Chapter 15: Molecule-Targeted
Drugs That Treat Colorectal Cancer. Chapter 16: Rising from the Ashes: The
Curious Case of the Development of Biologics for the Treatment of
Neuroblastoma. Chapter 17: Paradigm Shift in Cancer Therapy: Chimeric
Antigen Receptor T Cell Therapy. Chapter 18: Biologics and Biosimilars Used
for Diabetes. Chapter 19: Clinical Use of Biologics and Biosimilars in
Asthma. Chapter 20: Biologics and Biosimilars: Potential Therapeutics for
Autoimmune Renal Diseases. Chapter 21: Therapeutics of Recombinant Human
Clotting Factor VIII (rhFVIII) for Hemophilia A. Chapter 22: Complement as
New Immunotherapy Target: Past, Present, and Future. Chapter 23: Drug
Discovery Approaches for Inflammatory Bowel Disease: Antibodies and
Biosimilars. Chapter 24: Transformative Stem Cell-Based Therapy in
Neurological Diseases and Beyond. Chapter 25: Biologics and Biosimilars:
Clinical Applications and Biomarker Testing. Chapter 26: Application of
Modeling and Simulation in the Development of Biologics and Biosimilars.
Chapter 27 Machine Learning Applications in Biologics and Biosimilars:
Disruptive Innovation.